-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Zealand Pharma A/S (ZEAL)
-
-
-
-
-
-
-
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
-
-
-
-
-
-
-
Zealand Pharma Announces Financial Results for the First Quarter of 2023
-
-
-
-
-
-
-
Zealand Pharma Announces Financial Results for the First Half of 2022
-
-
-
-
-
-
-
Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.
-
-
-
-
-
-
-
Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection
-
-
-
-
-
-
-
Zealand Pharma continues to advance clinical programs and commercial launch capabilities and presents financial results for the first nine months of 2020
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

